Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
76.87
+0.81 (1.06%)
Aug 10, 2026, 12:24 PM EDT - Market open

KNSA Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
80.6659.01-43.1914.08183.36-157.92
Depreciation & Amortization
1.791.551.72.342.42.36
Stock-Based Compensation
42.073730.6927.1525.1225.17
Other Adjustments
19.415.6311.692.17-182.53.41
Change in Receivables
-20.42-2.7126.13-20.46-8.68-3.91
Changes in Inventories
-22.75-28.534.76-9.52-17.92-3.68
Changes in Accounts Payable
3.420.14-6.310.356.031.37
Changes in Accrued Expenses
48.7437.543.7316.94-3.7110.34
Changes in Unearned Revenue
-19.550.2616.712-
Changes in Other Operating Activities
-19.03-25.04-27.51-26.37-10.3-3.43
Operating Cash Flow
184.97137.9925.6913.35.81-126.3
Operating Cash Flow Growth
176.28%437.14%93.14%129.05%--
Capital Expenditures
-2.13-1.57-0.28-0.13-0.11-0.42
Sale of Property, Plant & Equipment
--0.03-0.09-
Purchases of Intangible Assets
------20
Purchases of Investments
-544.15-386.92-202.01-204.93-135.86-157.25
Proceeds from Sale of Investments
307.22199.49239.94175.51127.8306.3
Investing Cash Flow
-239.07-188.9937.67-29.56-8.08128.64
Issuance of Common Stock
48.840.7517.253.73.425.89
Repurchase of Common Stock
-11.06-7.73-4.98-2.21-0.9-
Net Common Stock Issued (Repurchased)
37.7433.0212.271.52.525.89
Financing Cash Flow
37.7433.0212.271.52.525.89
Net Cash Flow
-16.36-17.9975.63-14.760.258.22
Free Cash Flow
182.84136.4225.4113.175.7-126.71
Free Cash Flow Growth
174.98%436.82%92.94%130.99%--
FCF Margin
21.74%20.13%6.00%4.87%2.59%-328.75%
Free Cash Flow Per Share
2.231.730.360.180.08-1.85
Levered Free Cash Flow
90.762.61-26.8514.39171.76-151.39
Unlevered Free Cash Flow
88.7754.88-38.1521.62150.92-151.48
SEC Filings: 10-K · 10-Q